A study evaluating the interest of imatinib treatment maintenance or interruption after 3 years of adjuvant treatment in patients with Gastrointestinal Stromal Tumours
- Conditions
- GastroIntestinal Stromal Tumours (GIST)MedDRA version: 16.1Level: LLTClassification code 10062427Term: Gastrointestinal stromal tumorSystem Organ Class: 100000004864Therapeutic area: Diseases [C] - Cancer [C04]
- Registration Number
- EUCTR2013-001372-37-FR
- Lead Sponsor
- CENTRE LEON BERARD
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Recruiting
- Sex
- All
- Target Recruitment
- 256
I1.Age = 18 years at the day of consenting to the study
I2.Patients must have histologically confirmed diagnosis of localized GIST with documented KIT (CD117) positivity (by polyclonal DAKO antibody staining)
I3.Documented macroscopically complete surgical R0 or R1 resection of primary GIST lesion with no evidence of residual lesions or metastases on the baseline CT-scan or MRI performed no more than 4 weeks before randomization.
I4.Risk of tumor recurrence =35% according to National Comprehensive Cancer Network Task Force on GIST (NCCN) risk classification (Demetri et al., 2010) (adapted from Miettinen and Lasota, Seminars in Diagnostic Pathology 2006: 23(2) 70-83)
I5.ECOG performance status 0, 1 or 2
I6.Patients must be under imatinib treatment (at 300 or 400mg/day) initiated immediately after resection and maintained for 3 years (i.e. 36 months ± 3 months at the time of randomization) with no more than 3 consecutive months or 6 months in total of interruption during these 3 years.
I7.Patients must have normal organ and bone marrow function at baseline as defined below:
•Adequate bone marrow function as defined by: ANC = 1.5 x 109/L, platelet count = 100.0 x 109/L, and haemoglobin of = 9 g/dL).
•Adequate liver function, as determined by: Serum total bilirubin = 1.5 ULN, AST and ALT = 3 x ULN (or 5ULN in case of hepatic metastases at time of reintroduction)
•Adequate renal function assessed by at least one of the following:
1) Serum creatinine = 1.5 x ULN or
2) creatinine clearance estimate = 50 mL/min (as calculated according to Cockcroft-Gault formula or MDRD formula for patients > 65 years).
I8.Recovered from prior anti-neoplasic treatment-related toxicity (persistent treatment-related toxicity < Grade 2 as per CTCAE v4 are accepted)
I9.Women of childbearing potential* are required to have a negative serum pregnancy test within 72 hours prior to randomization. A positive urine test must be confirmed by a serum pregnancy test
I10.Patient must use two forms of effective contraception (refer to Appendix 3 for acceptable method of contraception) at least 4 weeks prior to study entry, during the study participation and for at least 30 days post-treatment (not applicable for women of non-childbearing potential)
I11.Ability to understand and willingness for follow-up visits.
I12.Covered by a medical insurance.
I13.Signed and dated informed consent document indicating that the patient has been informed of all aspects of the trial prior to enrolment.
Are the trial subjects under 18? no
Number of subjects for this age range:
F.1.2 Adults (18-64 years) yes
F.1.2.1 Number of subjects for this age range 256
F.1.3 Elderly (>=65 years) yes
F.1.3.1 Number of subjects for this age range 256
E1. Pregnant or breastfeeding women
E2. Patient concurrently using other approved or investigational antineoplastic agents
E3. Any contra-indication to imatinib treatment as per Glivec® SPC
E4. Patient with GIST harboring the mutation ; PDGFRa d842V
E5. Major concurrent disease affecting cardiovascular system, liver, kidneys, haematopoietic system or else considered as clinically important by the investigator and that could be incompatible with patient’s participation in this trial or would likely interfere with study procedures or results
E6. Prior history of other malignancies other than study disease (except for basal cell or squamous cell carcinoma of the skin or carcinoma in situ of the cervix) unless the subjects has been free of the disease for at least 3 years
E7. Patient receiving concurrent treatment with warfarin (acceptable alternative: low-molecular weight heparin) or any prohibited concomitant and/or concurrent medications
E8. Patient with Grade III/IV cardiac problems as defined by the New York Heart Association Criteria. (i.e., congestive heart failure, myocardial infarction within 6 months of study)
E9. Patient has a known diagnosis of human immunodeficiency virus (HIV) infection
E10. Major surgery within 2 weeks prior to study entry
Study & Design
- Study Type
- Interventional clinical trial of medicinal product
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method